Skip to main content
. Author manuscript; available in PMC: 2013 May 22.
Published in final edited form as: Pediatr Blood Cancer. 2009 May;52(5):621–625. doi: 10.1002/pbc.21838

Table IV. Comparison of Neurotoxicity in Study Group to Reference Group.

Group Study Reference
Treatment Dates 4/2004-10/2007 8/2001-3/2004
Treatment Protocol HLH-2004 or HLH-94 with early introduction of cyclosporine HLH-94
Number of Patients 17 15
Male/Female 5/12 9/6
Age (yrs)
Range
Median
0.1-16
4.9
0.2-12
1.6
CNS Status at Diagnosis
(CNS Dz +/-)
4/13 3/12
Survival
(Alive/Deceased)
7/10 8/7
Neurotoxicity
(Present/Absent)
5/12 1/14
HHS Vulnerability Disclosure